MENU
+Compare
EDAP
Stock ticker: NASDAQ
AS OF
Dec 26, 10:46 AM (EDT)
Price
$3.09
Change
+$0.12 (+4.04%)
Capitalization
111.06M

EDAP stock forecast, quote, news & analysis

Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution... Show more

Industry: #Biotechnology
EDAP
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. EDAP showed earnings on November 06, 2025. You can read more about the earnings report here.
Interact to see
Advertisement
A.I.Advisor
a Summary for EDAP with price predictions
Dec 24, 2025

Aroon Indicator for EDAP shows an upward move is likely

EDAP's Aroon Indicator triggered a bullish signal on December 24, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 150 similar instances where the Aroon Indicator showed a similar pattern. In of the 150 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on December 12, 2025. You may want to consider a long position or call options on EDAP as a result. In of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

EDAP moved above its 50-day moving average on November 25, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for EDAP crossed bullishly above the 50-day moving average on November 28, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where EDAP advanced for three days, in of 242 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for EDAP moved out of overbought territory on December 17, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 50 cases where EDAP's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EDAP declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

EDAP broke above its upper Bollinger Band on December 12, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. EDAP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.037) is normal, around the industry mean (9.533). P/E Ratio (0.000) is within average values for comparable stocks, (30.459). EDAP's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.587). Dividend Yield (0.000) settles around the average of (0.029) among similar stocks. P/S Ratio (1.432) is also within normal values, averaging (141.622).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EDAP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are McKesson Corp (NYSE:MCK).

Industry description

Healthcare distribution market can be segmented into pharmaceutical product distribution services, medical device distribution services, and biopharmaceutical product distribution services. In addition to serving as intermediaries, many medical distributors also purchase and take legal ownership of pharmaceuticals and manage inventory and credit risk. According to a Deloitte report, pharmaceutical distributors’ core services of efficient product distribution, inventory management, financial risk management, and information-sharing generate $33 billion-$53 billion in value annually to the U.S. health care ecosystem. Some prominent players in the overall medical distribution industry include McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc. and Patterson Companies, Inc.

Market Cap

The average market capitalization across the Medical Distributors Industry is 11.82B. The market cap for tickers in the group ranges from 557.05K to 102B. MCK holds the highest valuation in this group at 102B. The lowest valued company is CNBI at 557.05K.

High and low price notable news

The average weekly price growth across all stocks in the Medical Distributors Industry was 4%. For the same Industry, the average monthly price growth was 1%, and the average quarterly price growth was 2%. EXHI experienced the highest price growth at 145%, while ZYXI experienced the biggest fall at -53%.

Volume

The average weekly volume growth across all stocks in the Medical Distributors Industry was 124%. For the same stocks of the Industry, the average monthly volume growth was 43% and the average quarterly volume growth was 90%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 63
P/E Growth Rating: 54
Price Growth Rating: 58
SMR Rating: 82
Profit Risk Rating: 81
Seasonality Score: 34 (-100 ... +100)
View a ticker or compare two or three
EDAP
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a developer of minimally invasive medical devices for urological diseases

Industry MedicalDistributors

Profile
Fundamentals
Details
Industry
Biotechnology
Address
Parc d'Activites La Poudrette-Lamartine
Phone
+33 472153150
Employees
307
Web
https://www.edap-tms.com